BioCentury
ARTICLE | Company News

Depomed, Impax, Par Pharmaceutical, Watson neurology news

January 7, 2013 8:00 AM UTC

Depomed said on Dec. 26, 2012, that the U.S. District Court for the District of New Jersey dismissed two patent infringement suits against Par and Watson relating to ANDAs for generic versions of Depomed's Gralise gabapentin. The parties requested the cases be dismissed after Watson withdrew its ANDA and Par amended its ANDA so that it will not seek approval from FDA prior to the September 2014 expiration of the Gralise Orange Book patents. Last October, Depomed said that the court dismissed patent litigation against Impax after the manufacturer withdrew its ANDA for a generic version of Gralise. Depomed said that three patent infringement suits relating to ANDAs for generic Gralise are still pending in the New Jersey court. ...